• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/8/24 8:05:59 AM ET
    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELTX alert in real time by email

    Gainers

    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap stands at $2.2 million.
    • Titan Pharma (NASDAQ:TTNP) stock moved upwards by 27.59% to $8.0. The company's market cap stands at $6.0 million.
    • Trxade Health (NASDAQ:MEDS) shares rose 18.73% to $5.32. The company's market cap stands at $6.4 million.
    • Elicio Therapeutics (NASDAQ:ELTX) shares moved upwards by 17.8% to $3.97. The company's market cap stands at $38.1 million.
    • Nutex Health (NASDAQ:NUTX) stock increased by 17.63% to $0.13. The market value of their outstanding shares is at $97.9 million.
    • Mineralys Therapeutics (NASDAQ:MLYS) shares rose 16.51% to $14.53. The market value of their outstanding shares is at $597.2 million.

    Losers

    • Jin Medical International (NASDAQ:ZJYL) shares decreased by 93.9% to $13.26 during Thursday's pre-market session. The market value of their outstanding shares is at $103.7 million.
    • Tenax Therapeutics (NASDAQ:TENX) shares fell 52.39% to $6.79. The company's market cap stands at $2.3 million.
    • InVivo Therapeutics Hldg (NASDAQ:NVIV) stock declined by 17.61% to $0.53. The company's market cap stands at $1.6 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) shares declined by 13.6% to $0.58. The market value of their outstanding shares is at $57.6 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares fell 13.1% to $0.73. The company's market cap stands at $2.2 million.
    • Exicure (NASDAQ:XCUR) stock declined by 13.02% to $0.59. The company's market cap stands at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ELTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELTX
    $HOOK
    $MEDS
    $MLYS

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Mineralys Therapeutics Inc.
    $MLYS
    6/11/2025$15.00Hold
    Jefferies
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Tenax Therapeutics Inc.
    $TENX
    10/24/2024$16.00Outperform
    Leerink Partners
    Tenax Therapeutics Inc.
    $TENX
    10/14/2024$16.00Buy
    Guggenheim
    Tenax Therapeutics Inc.
    $TENX
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Elicio Therapeutics Inc.

    S-3/A - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/2/26 4:05:36 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Elicio Therapeutics Inc.

    S-3 - Elicio Therapeutics, Inc. (0001601485) (Filer)

    2/27/26 4:15:38 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXICURE, INC. (0001698530) (Filer)

    2/17/26 5:25:17 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Mineralys Therapeutics with a new price target

    Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

    6/11/25 7:54:20 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

    CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Stuart Rich, M.D., Chief Medical Officer; Douglas Randall, Chief Business OfficerDate and Time: March 10, 2026, at 2:20 p.m. ET The

    3/3/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to one new non-executive employee. The awards were granted under Mineralys' 2025 Employment Induc

    2/26/26 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. was granted 6,200 shares (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    2/20/26 7:49:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sblendorio Glenn was granted 6,200 shares (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    2/20/26 7:47:36 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Congleton Jon was granted 140,900 shares, increasing direct ownership by 22% to 780,051 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    2/20/26 7:47:45 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Leadership Updates

    Live Leadership Updates

    View All

    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

    BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

    11/19/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

    HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the

    5/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Financials

    Live finance-specific insights

    View All

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    NUTEX HEALTH REPORTS SEPTEMBER 30, 2025 THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS

    Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5%Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 millionDiluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4%Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for th

    11/19/25 4:30:00 PM ET
    $NUTX
    Real Estate

    Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. "We c

    11/12/25 4:05:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care